Cargando…

A standardised framework to identify optimal animal models for efficacy assessment in drug development

INTRODUCTION: Poor translation of efficacy data derived from animal models can lead to clinical trials unlikely to benefit patients–or even put them at risk–and is a potential contributor to costly and unnecessary attrition in drug development. OBJECTIVES: To develop a tool to assess, validate and c...

Descripción completa

Detalles Bibliográficos
Autores principales: S. Ferreira, Guilherme, Veening-Griffioen, Désirée H., Boon, Wouter P. C., Moors, Ellen H. M., Gispen-de Wied, Christine C., Schellekens, Huub, van Meer, Peter J. K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6563989/
https://www.ncbi.nlm.nih.gov/pubmed/31194784
http://dx.doi.org/10.1371/journal.pone.0218014
_version_ 1783426632940257280
author S. Ferreira, Guilherme
Veening-Griffioen, Désirée H.
Boon, Wouter P. C.
Moors, Ellen H. M.
Gispen-de Wied, Christine C.
Schellekens, Huub
van Meer, Peter J. K.
author_facet S. Ferreira, Guilherme
Veening-Griffioen, Désirée H.
Boon, Wouter P. C.
Moors, Ellen H. M.
Gispen-de Wied, Christine C.
Schellekens, Huub
van Meer, Peter J. K.
author_sort S. Ferreira, Guilherme
collection PubMed
description INTRODUCTION: Poor translation of efficacy data derived from animal models can lead to clinical trials unlikely to benefit patients–or even put them at risk–and is a potential contributor to costly and unnecessary attrition in drug development. OBJECTIVES: To develop a tool to assess, validate and compare the clinical translatability of animal models used for the preliminary assessment of efficacy. DESIGN AND RESULTS: We performed a scoping review to identify the key aspects used to validate animal models. Eight domains (Epidemiology, Symptomatology and Natural History–SNH, Genetic, Biochemistry, Aetiology, Histology, Pharmacology and Endpoints) were identified. We drafted questions to evaluate the different facets of human disease simulation. We designed the Framework to Identify Models of Disease (FIMD) to include standardised instructions, a weighting and scoring system to compare models as well as factors to help interpret model similarity and evidence uncertainty. We also added a reporting quality and risk of bias assessment of drug intervention studies in the Pharmacological Validation domain. A web-based survey was conducted with experts from different stakeholders to gather input on the framework. We conducted a pilot study of the validation in two models for Type 2 Diabetes (T2D)–the ZDF rat and db/db mouse. Finally, we present a full validation and comparison of two animal models for Duchenne Muscular Dystrophy (DMD): the mdx mouse and GRMD dog. We show that there are significant differences between the mdx mouse and the GRMD dog, the latter mimicking the human epidemiological, SNH, and histological aspects to a greater extent than the mouse despite the overall lack of published data. CONCLUSIONS: FIMD facilitates drug development by serving as the basis to select the most relevant model that can provide meaningful data and is more likely to generate translatable results to progress drug candidates to the clinic.
format Online
Article
Text
id pubmed-6563989
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-65639892019-06-20 A standardised framework to identify optimal animal models for efficacy assessment in drug development S. Ferreira, Guilherme Veening-Griffioen, Désirée H. Boon, Wouter P. C. Moors, Ellen H. M. Gispen-de Wied, Christine C. Schellekens, Huub van Meer, Peter J. K. PLoS One Research Article INTRODUCTION: Poor translation of efficacy data derived from animal models can lead to clinical trials unlikely to benefit patients–or even put them at risk–and is a potential contributor to costly and unnecessary attrition in drug development. OBJECTIVES: To develop a tool to assess, validate and compare the clinical translatability of animal models used for the preliminary assessment of efficacy. DESIGN AND RESULTS: We performed a scoping review to identify the key aspects used to validate animal models. Eight domains (Epidemiology, Symptomatology and Natural History–SNH, Genetic, Biochemistry, Aetiology, Histology, Pharmacology and Endpoints) were identified. We drafted questions to evaluate the different facets of human disease simulation. We designed the Framework to Identify Models of Disease (FIMD) to include standardised instructions, a weighting and scoring system to compare models as well as factors to help interpret model similarity and evidence uncertainty. We also added a reporting quality and risk of bias assessment of drug intervention studies in the Pharmacological Validation domain. A web-based survey was conducted with experts from different stakeholders to gather input on the framework. We conducted a pilot study of the validation in two models for Type 2 Diabetes (T2D)–the ZDF rat and db/db mouse. Finally, we present a full validation and comparison of two animal models for Duchenne Muscular Dystrophy (DMD): the mdx mouse and GRMD dog. We show that there are significant differences between the mdx mouse and the GRMD dog, the latter mimicking the human epidemiological, SNH, and histological aspects to a greater extent than the mouse despite the overall lack of published data. CONCLUSIONS: FIMD facilitates drug development by serving as the basis to select the most relevant model that can provide meaningful data and is more likely to generate translatable results to progress drug candidates to the clinic. Public Library of Science 2019-06-13 /pmc/articles/PMC6563989/ /pubmed/31194784 http://dx.doi.org/10.1371/journal.pone.0218014 Text en © 2019 S. Ferreira et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
S. Ferreira, Guilherme
Veening-Griffioen, Désirée H.
Boon, Wouter P. C.
Moors, Ellen H. M.
Gispen-de Wied, Christine C.
Schellekens, Huub
van Meer, Peter J. K.
A standardised framework to identify optimal animal models for efficacy assessment in drug development
title A standardised framework to identify optimal animal models for efficacy assessment in drug development
title_full A standardised framework to identify optimal animal models for efficacy assessment in drug development
title_fullStr A standardised framework to identify optimal animal models for efficacy assessment in drug development
title_full_unstemmed A standardised framework to identify optimal animal models for efficacy assessment in drug development
title_short A standardised framework to identify optimal animal models for efficacy assessment in drug development
title_sort standardised framework to identify optimal animal models for efficacy assessment in drug development
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6563989/
https://www.ncbi.nlm.nih.gov/pubmed/31194784
http://dx.doi.org/10.1371/journal.pone.0218014
work_keys_str_mv AT sferreiraguilherme astandardisedframeworktoidentifyoptimalanimalmodelsforefficacyassessmentindrugdevelopment
AT veeninggriffioendesireeh astandardisedframeworktoidentifyoptimalanimalmodelsforefficacyassessmentindrugdevelopment
AT boonwouterpc astandardisedframeworktoidentifyoptimalanimalmodelsforefficacyassessmentindrugdevelopment
AT moorsellenhm astandardisedframeworktoidentifyoptimalanimalmodelsforefficacyassessmentindrugdevelopment
AT gispendewiedchristinec astandardisedframeworktoidentifyoptimalanimalmodelsforefficacyassessmentindrugdevelopment
AT schellekenshuub astandardisedframeworktoidentifyoptimalanimalmodelsforefficacyassessmentindrugdevelopment
AT vanmeerpeterjk astandardisedframeworktoidentifyoptimalanimalmodelsforefficacyassessmentindrugdevelopment
AT sferreiraguilherme standardisedframeworktoidentifyoptimalanimalmodelsforefficacyassessmentindrugdevelopment
AT veeninggriffioendesireeh standardisedframeworktoidentifyoptimalanimalmodelsforefficacyassessmentindrugdevelopment
AT boonwouterpc standardisedframeworktoidentifyoptimalanimalmodelsforefficacyassessmentindrugdevelopment
AT moorsellenhm standardisedframeworktoidentifyoptimalanimalmodelsforefficacyassessmentindrugdevelopment
AT gispendewiedchristinec standardisedframeworktoidentifyoptimalanimalmodelsforefficacyassessmentindrugdevelopment
AT schellekenshuub standardisedframeworktoidentifyoptimalanimalmodelsforefficacyassessmentindrugdevelopment
AT vanmeerpeterjk standardisedframeworktoidentifyoptimalanimalmodelsforefficacyassessmentindrugdevelopment